Advanced Proteome Therapeutics Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APTCF research report →
Companywww.advancedproteome.com
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc. , operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics.
- CEO
- Benjamin Krantz
- IPO
- 2009
- HQ
- Burnaby, BC, CA
Price Chart
Valuation
- Market Cap
- $149.63K
- P/E
- 0.01
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 0.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 198.18%
- ROIC
- 186.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $759.62K · 141.41%
- EPS
- $0.02 · 132.71%
- Op Income
- $-940,859
- FCF YoY
- -29.34%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.41
- Avg Volume
- 9.99K
Get TickerSpark's AI analysis on APTCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our APTCF Coverage
We haven't published any research on APTCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APTCF Report →